Rezdiffra (Resmetirom) Missed-Dose Protocol: What to Do If You Skip a Dose

What the Prescribing Information Says About Missed Doses

The FDA-approved Rezdiffra prescribing information provides a straightforward missed-dose instruction: if a dose is missed, take it as soon as you remember on the same day, then resume the regular once-daily schedule the following day 1. Never take two doses on the same day to compensate.

Same-Day Window

This "same-day" phrasing is deliberate. Resmetirom's pharmacokinetic profile supports a generous recovery window. The drug reaches peak plasma concentration (Tmax) approximately 4 hours after oral administration 1. Because its elimination half-life spans roughly 50 hours, a single missed dose does not immediately collapse drug levels below the therapeutic threshold 2.

When to Skip Entirely

If you realize you missed your dose late in the evening and your next dose is due the following morning, skipping the missed dose entirely is the safer choice. Taking two doses within a compressed timeframe could transiently amplify thyroid hormone receptor activation without offering additional histological benefit.

How Resmetirom Works and Why Consistency Matters

Resmetirom is a selective agonist of thyroid hormone receptor beta (THR-β), the dominant thyroid receptor isoform in the liver 3. By binding THR-β without activating THR-α (which governs cardiac rate and bone turnover), resmetirom lowers intrahepatic lipid content, reduces inflammatory gene expression, and improves markers of fibrogenesis 4.

Hepatic Selectivity

The drug's selectivity for hepatic THR-β over extrahepatic THR-α explains both its efficacy in MASH and its relatively favorable safety profile. In the MAESTRO-NASH trial, no clinically significant increases in heart rate were observed at either the 80 mg or 100 mg dose 2. Bone mineral density remained stable through 52 weeks of treatment 5.

The Lipid Metabolism Pathway

THR-β activation upregulates genes involved in mitochondrial fatty acid beta-oxidation, reduces hepatic de novo lipogenesis, and lowers circulating LDL cholesterol by increasing LDL receptor expression 6. In MAESTRO-NASH, mean LDL cholesterol dropped by approximately 14% from baseline at week 52 compared with a 1% reduction in placebo 2. These metabolic shifts require sustained receptor occupancy. A missed dose does not erase weeks of treatment, but chronic non-adherence degrades the steady-state drug levels needed for ongoing hepatic fat reduction 7.

Pharmacokinetics That Shape the Missed-Dose Window

Understanding resmetirom's pharmacokinetic profile makes the missed-dose guidance intuitive rather than arbitrary.

Absorption and Food Effect

Resmetirom should be taken with food. The FDA label notes that a moderate-fat meal increases the area under the curve (AUC) and reduces pharmacokinetic variability compared with fasting administration 1. A Phase 1 food-effect study confirmed that co-administration with a meal improved bioavailability by roughly 25% 8.

Half-Life and Steady State

With a terminal elimination half-life of approximately 50 hours, resmetirom takes roughly 10 to 12 days of daily dosing to reach steady-state plasma concentrations 1. At steady state, the trough-to-peak fluctuation is modest. This means a single skipped dose will reduce trough levels by a calculable fraction (approximately 25% to 30% based on half-life math), but the drug does not wash out.

Protein Binding and Distribution

Resmetirom is highly protein-bound (greater than 99%), primarily to albumin 1. Patients with advanced liver disease and hypoalbuminemia could theoretically experience altered free-drug fractions. The MAESTRO-NASH trial enrolled patients with compensated cirrhosis (Child-Pugh A), but excluded decompensated liver disease 2. No dose adjustment for mild hepatic impairment is currently recommended in the label 1.

What MAESTRO-NASH Tells Us About Sustained Dosing

MAESTRO-NASH (N=966) remains the key trial behind resmetirom's accelerated approval for MASH with moderate-to-advanced liver fibrosis (stage F2 or F3) 2.

Primary Endpoints

At 52 weeks, MASH resolution without worsening of fibrosis occurred in 25.9% of patients receiving 80 mg and 29.9% receiving 100 mg, versus 9.7% with placebo 2. Fibrosis improvement by at least one stage (with no worsening of NAFLD Activity Score) was achieved in 24.2% at 80 mg and 25.9% at 100 mg, compared with 14.2% for placebo 2.

Adherence in the Trial

Trial participants were required to take the drug daily under protocol-specified conditions. Compliance rates exceeded 90% across treatment arms, as measured by pill counts and patient diaries 2. The histological benefits demonstrated in MAESTRO-NASH reflect this high adherence rate. No subgroup analysis has been published examining outcomes in patients who missed more than a defined number of doses.

Earlier Supporting Data

A Phase 2 trial (N=125) over 36 weeks showed that resmetirom 80 mg daily produced a relative reduction in hepatic fat fraction of 32.9% by MRI-PDFF, compared with a 10.4% relative reduction with placebo 9. This earlier dataset confirmed that the drug's pharmacodynamic effect on liver fat requires weeks of continuous therapy, reinforcing the importance of daily adherence 10.

Weight-Based Dosing and How It Interacts with Missed Doses

Rezdiffra uses a weight-based dosing scheme. Patients weighing less than 100 kg receive 80 mg once daily, while those at or above 100 kg take 100 mg once daily 1.

Why Weight Matters

Resmetirom's volume of distribution increases with body mass. Higher-weight patients require the 100 mg dose to achieve comparable hepatic drug exposure 8. If a patient at 100 kg or above misses a dose of the 100 mg tablet, the proportional decline in steady-state trough concentration is similar to the 80 mg scenario. The half-life does not change meaningfully with weight.

Do Not Substitute Doses

A patient prescribed 100 mg should not take two 80 mg tablets if they run out of 100 mg supply. The label-specified dose is the one that was studied in the registrational trial 2. If supply disruptions cause repeated missed doses, contact the prescribing clinician for guidance.

Safety Considerations After a Missed Dose

Resmetirom carries specific safety signals that patients and clinicians should keep in mind when managing dose interruptions.

Thyroid Function

Despite being a thyroid receptor agonist, resmetirom does not suppress the hypothalamic-pituitary-thyroid axis at approved doses. TSH levels remained within normal range in MAESTRO-NASH 2. A single missed dose does not create a rebound effect on thyroid parameters.

Hepatotoxicity Monitoring

The FDA label includes a warning to monitor liver enzymes before and during treatment 1. In MAESTRO-NASH, ALT elevations greater than 3 times the upper limit of normal occurred at similar rates across treatment and placebo arms. A missed dose does not alter the recommended monitoring schedule.

Gallbladder Events

Cholelithiasis and cholecystitis were reported at slightly higher rates in the resmetirom group compared with placebo in MAESTRO-NASH 2. The mechanism is thought to relate to increased biliary cholesterol secretion from THR-β activation 11. Sporadic missed doses do not clearly modify gallbladder risk, but patients should report right upper quadrant pain regardless of adherence patterns.

Drug Interactions

Resmetirom is metabolized primarily by CYP2C8 and CYP3A4 1. Strong CYP2C8 inhibitors (such as gemfibrozil) are contraindicated because they approximately double resmetirom exposure. A missed dose followed by resumption alongside an interacting medication does not require dose adjustment beyond what the label already specifies. The AASLD 2023 practice guidance notes that drug interaction screening should occur at initiation and at each follow-up visit 12.

Practical Adherence Strategies

Maintaining daily adherence to resmetirom maximizes the chance of achieving the histological improvements documented in MAESTRO-NASH.

Anchor the Dose to a Meal

Since resmetirom requires food for optimal absorption 1, tying the dose to a consistent daily meal (breakfast or lunch) creates a reliable behavioral cue. Patients who skip breakfast regularly may consider pairing the dose with their first meal of the day, whenever that occurs.

Use a Pill Organizer or Phone Alarm

Simple. A 2019 systematic review of medication adherence interventions in chronic liver disease found that electronic reminders improved adherence rates by 12% to 18% compared with standard care 13.

Track Missed Doses for Your Clinician

If you miss more than two doses in any given week, document the dates. Your prescribing physician may factor adherence into the decision about whether to continue, adjust, or augment therapy. The AASLD emphasizes that treatment response assessment (via non-invasive biomarkers or repeat biopsy) at 52 weeks should account for real-world adherence 14.

Where Resmetirom Fits in MASH Treatment

Rezdiffra's March 2024 accelerated approval made it the first drug specifically indicated for MASH with liver fibrosis 15. Before this approval, MASH management relied on weight loss (via lifestyle intervention or GLP-1 receptor agonists off-label), pioglitazone, and vitamin E 12.

Ongoing Confirmatory Trials

The accelerated approval requires Madrigal to complete MAESTRO-NASH Part 2, a long-term outcomes study evaluating whether resmetirom reduces progression to cirrhosis, liver transplantation, and liver-related mortality 16. Results are expected by 2028. Until then, sustained adherence to the prescribed dose is necessary to replicate the histological benefit seen in the 52-week data.

Combination Approaches Under Investigation

Early-phase studies are examining resmetirom in combination with GLP-1 receptor agonists like semaglutide, given that both drug classes reduce hepatic steatosis through complementary mechanisms 17. If combination regimens become standard, missed-dose protocols will need to account for the pharmacokinetics of both agents.

The prescribing information recommends monitoring liver function tests at baseline, during dose titration, and periodically thereafter. Patients who miss doses should not alter their monitoring schedule. The next scheduled lab draw proceeds as planned 1.